{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:38:11Z","timestamp":1784608691831,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Sir David Todd Professorship in Medicine"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-06431-w","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T19:20:13Z","timestamp":1751397613000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Serum Tsukushi level is negatively associated with cholesterol efflux capacity in metabolic dysfunction-associated steatotic liver disease: a cross-sectional study"],"prefix":"10.1038","volume":"15","author":[{"given":"Sum","family":"Lam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T. W.","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol H. Y.","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sammy W. M.","family":"Shiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen S. L.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lung-Yi","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man-Fung","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7569-409X","authenticated-orcid":false,"given":"Chi-Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9037-0416","authenticated-orcid":false,"given":"Kathryn Choon-Beng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"6431_CR1","doi-asserted-by":"publisher","first-page":"101133","DOI":"10.1016\/j.aohep.2023.101133","volume":"29","author":"ME Rinella","year":"2024","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann. Hepatol. 29, 101133 (2024).","journal-title":"Ann. Hepatol."},{"key":"6431_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7570\/jomes23052","volume":"32","author":"WK Chan","year":"2023","unstructured":"Chan, W. K. et al. Metabolic Dysfunction-Associated steatotic liver disease (MASLD): A State-of-the-Art review. J. Obes. Metab. Syndr. 32, 197\u2013213 (2023).","journal-title":"J. Obes. Metab. Syndr."},{"key":"6431_CR3","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi, K. et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 7, 851\u2013861 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"6431_CR4","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejim.2023.11.012","volume":"122","author":"A Mellemkjaer","year":"2024","unstructured":"Mellemkjaer, A., Kjaer, M. B., Haldrup, D., Gronbaek, H. & Thomsen, K. L. Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease. Eur. J. Intern. Med. 122, 28\u201334 (2024).","journal-title":"Eur. J. Intern. Med."},{"key":"6431_CR5","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.4239\/wjd.v12.i9.1479","volume":"12","author":"R Khandelwal","year":"2021","unstructured":"Khandelwal, R., Dassanayake, A. S., Conjeevaram, H. S. & Singh, S. P. Non-alcoholic fatty liver disease in diabetes: when to refer to the hepatologist? World J. Diabetes. 12, 1479\u20131493 (2021).","journal-title":"World J. Diabetes"},{"key":"6431_CR6","doi-asserted-by":"publisher","first-page":"e1003100","DOI":"10.1371\/journal.pmed.1003100","volume":"17","author":"H Jarvis","year":"2020","unstructured":"Jarvis, H. et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. PLoS Med. 17, e1003100 (2020).","journal-title":"PLoS Med."},{"key":"6431_CR7","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s12079-022-00669-z","volume":"16","author":"A Istiaq","year":"2022","unstructured":"Istiaq, A. & Ohta, K. A review on tsukushi: mammalian development, disorders, and therapy. J. Cell. Commun. Signal. 16, 505\u2013513 (2022).","journal-title":"J. Cell. Commun. Signal."},{"key":"6431_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.devcel.2004.08.014","volume":"7","author":"K Ohta","year":"2004","unstructured":"Ohta, K. et al. Tsukushi functions as an organizer inducer by Inhibition of BMP activity in Cooperation with Chordin. Dev. Cell. 7, 347\u2013358 (2004).","journal-title":"Dev. Cell."},{"key":"6431_CR9","doi-asserted-by":"crossref","unstructured":"Mouchiroud, M. et al., The hepatokine Tsukushi is released in response to NAFLD and impacts cholesterol homeostasis. JCI Insight 4 (2019).","DOI":"10.1172\/jci.insight.129492"},{"key":"6431_CR10","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.2337\/db21-0161","volume":"70","author":"Q Wang","year":"2021","unstructured":"Wang, Q. et al. Deletion of the Feeding-Induced hepatokine TSK ameliorates the melanocortin obesity syndrome. Diabetes 70, 2081\u20132091 (2021).","journal-title":"Diabetes"},{"key":"6431_CR11","doi-asserted-by":"crossref","unstructured":"Lam, S. et al., Serum Tsukushi level is associated with the severity of liver fibrosis independent of type 2 diabetes. J Clin. Endocrinol. Metab (2023).","DOI":"10.1210\/clinem\/dgad650"},{"key":"6431_CR12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.molmet.2018.12.004","volume":"20","author":"X Xiong","year":"2019","unstructured":"Xiong, X. et al. Mapping the molecular signatures of diet-induced NASH and its regulation by the hepatokine Tsukushi. Mol. Metab. 20, 128\u2013137 (2019).","journal-title":"Mol. Metab."},{"key":"6431_CR13","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.33549\/physiolres.933585","volume":"66","author":"R Poledne","year":"2017","unstructured":"Poledne, R. & Jurcikova-Novotna, L. Experimental models of hyperlipoproteinemia and atherosclerosis. Physiol. Res. 66, S69\u2013S75 (2017).","journal-title":"Physiol. Res."},{"key":"6431_CR14","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.cgh.2014.10.008","volume":"13","author":"MS Siddiqui","year":"2015","unstructured":"Siddiqui, M. S. et al. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile. Clin. Gastroenterol. Hepatol. 13, 1000\u20131008e1003 (2015).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"6431_CR15","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1161\/CIRCRESAHA.119.312617","volume":"124","author":"M Ouimet","year":"2019","unstructured":"Ouimet, M., Barrett, T. J. & Fisher, E. A. HDL and reverse cholesterol transport. Circ. Res. 124, 1505\u20131518 (2019).","journal-title":"Circ. Res."},{"key":"6431_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/MOL.0000000000000589","volume":"30","author":"D Rhainds","year":"2019","unstructured":"Rhainds, D. & Tardif, J. C. From HDL-cholesterol to HDL-function: cholesterol efflux capacity determinants. Curr. Opin. Lipidol. 30, 101\u2013107 (2019).","journal-title":"Curr. Opin. Lipidol."},{"key":"6431_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1056\/NEJMoa1001689","volume":"364","author":"AV Khera","year":"2011","unstructured":"Khera, A. V. et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl. J. Med. 364, 127\u2013135 (2011).","journal-title":"N Engl. J. Med."},{"key":"6431_CR18","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","volume":"371","author":"A Rohatgi","year":"2014","unstructured":"Rohatgi, A. et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl. J. Med. 371, 2383\u20132393 (2014).","journal-title":"N Engl. J. Med."},{"key":"6431_CR19","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S2213-8587(15)00126-6","volume":"3","author":"D Saleheen","year":"2015","unstructured":"Saleheen, D. et al. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes Endocrinol. 3, 507\u2013513 (2015).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"6431_CR20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.atherosclerosis.2015.10.111","volume":"249","author":"C Liu","year":"2016","unstructured":"Liu, C. et al. Cholesterol efflux capacity is an independent predictor of all-cause and cardiovascular mortality in patients with coronary artery disease: A prospective cohort study. Atherosclerosis 249, 116\u2013124 (2016).","journal-title":"Atherosclerosis"},{"key":"6431_CR21","doi-asserted-by":"publisher","first-page":"11691","DOI":"10.1038\/s41598-018-29639-5","volume":"8","author":"R Fadaei","year":"2018","unstructured":"Fadaei, R. et al. Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis. Sci. Rep. 8, 11691 (2018).","journal-title":"Sci. Rep."},{"key":"6431_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.atherosclerosis.2018.07.028","volume":"277","author":"EH van den Berg","year":"2018","unstructured":"van den Berg, E. H. et al. Cholesterol efflux capacity is impaired in subjects with an elevated fatty liver index, a proxy of non-alcoholic fatty liver disease. Atherosclerosis 277, 21\u201327 (2018).","journal-title":"Atherosclerosis"},{"key":"6431_CR23","doi-asserted-by":"crossref","unstructured":"Bonilha, I., Zimetti, F., Zanotti, I., Papotti, B. & Sposito, A. C. Dysfunctional high-density lipoproteins in type 2 diabetes mellitus: molecular mechanisms and therapeutic implications. J Clin. Med 10 (2021).","DOI":"10.3390\/jcm10112233"},{"key":"6431_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5551\/jat.5447","volume":"18","author":"I Sugino","year":"2011","unstructured":"Sugino, I. et al. Influence of fatty liver on plasma small, dense LDL- cholesterol in subjects with and without metabolic syndrome. J. Atheroscler Thromb. 18, 1\u20137 (2011).","journal-title":"J. Atheroscler Thromb."},{"key":"6431_CR25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.cca.2014.07.017","volume":"438","author":"K Kikkawa","year":"2015","unstructured":"Kikkawa, K. et al. Small dense LDL cholesterol measured by homogeneous assay in Japanese healthy controls, metabolic syndrome and diabetes patients with or without a fatty liver. Clin. Chim. Acta. 438, 70\u201379 (2015).","journal-title":"Clin. Chim. Acta"},{"key":"6431_CR26","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1210\/jc.2015-3111","volume":"101","author":"F Bril","year":"2016","unstructured":"Bril, F. et al. Hepatic steatosis and insulin resistance, but not steatohepatitis, promote atherogenic dyslipidemia in NAFLD. J. Clin. Endocrinol. Metab. 101, 644\u2013652 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"6431_CR27","doi-asserted-by":"publisher","first-page":"366","DOI":"10.2337\/dc07-1558","volume":"31","author":"K Kantartzis","year":"2008","unstructured":"Kantartzis, K. et al. Fatty liver is independently associated with alterations in Circulating HDL2 and HDL3 subfractions. Diabetes Care. 31, 366\u2013368 (2008).","journal-title":"Diabetes Care"},{"key":"6431_CR28","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1210\/clinem\/dgac565","volume":"108","author":"F Bril","year":"2022","unstructured":"Bril, F., Pearce, R. W., Collier, T. S. & McPhaul, M. J. Differences in HDL-Bound apolipoproteins in patients with advanced liver fibrosis due to nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 108, 42\u201351 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"6431_CR29","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/jdi.12487","volume":"7","author":"K Tan","year":"2016","unstructured":"Tan, K. Re-examining the high-density lipoprotein hypothesis. J. Diabetes Investig. 7, 445\u2013447 (2016).","journal-title":"J. Diabetes Investig"},{"key":"6431_CR30","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1161\/ATVBAHA.109.199158","volume":"30","author":"M de la Llera-Moya","year":"2010","unstructured":"de la Llera-Moya, M. et al. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler. Thromb. Vasc Biol. 30, 796\u2013801 (2010).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"key":"6431_CR31","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1124\/pr.58.3.1","volume":"58","author":"A Kontush","year":"2006","unstructured":"Kontush, A. & Chapman, M. J. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol. Rev. 58, 342\u2013374 (2006).","journal-title":"Pharmacol. Rev."},{"key":"6431_CR32","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1194\/jlr.M700274-JLR200","volume":"48","author":"MP Adorni","year":"2007","unstructured":"Adorni, M. P. et al. The roles of different pathways in the release of cholesterol from macrophages. J. Lipid Res. 48, 2453\u20132462 (2007).","journal-title":"J. Lipid Res."},{"key":"6431_CR33","doi-asserted-by":"publisher","first-page":"774418","DOI":"10.3389\/fcvm.2021.774418","volume":"8","author":"JJ Lee","year":"2021","unstructured":"Lee, J. J. et al. Cholesterol efflux capacity and its association with adverse cardiovascular events: A systematic review and Meta-Analysis. Front. Cardiovasc. Med. 8, 774418 (2021).","journal-title":"Front. Cardiovasc. Med."},{"key":"6431_CR34","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1177\/1479164109344934","volume":"6","author":"H Zhou","year":"2009","unstructured":"Zhou, H., Shiu, S. W., Wong, Y. & Tan, K. C. Impaired serum capacity to induce cholesterol efflux is associated with endothelial dysfunction in type 2 diabetes mellitus. Diab Vasc Dis. Res. 6, 238\u2013243 (2009).","journal-title":"Diab Vasc Dis. Res."},{"key":"6431_CR35","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1161\/CIRCRESAHA.120.317178","volume":"127","author":"Y He","year":"2020","unstructured":"He, Y. et al. Diabetes impairs cellular cholesterol efflux from ABCA1 to small HDL particles. Circ. Res. 127, 1198\u20131210 (2020).","journal-title":"Circ. Res."},{"key":"6431_CR36","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11010-017-3165-z","volume":"440","author":"RAK Srivastava","year":"2018","unstructured":"Srivastava, R. A. K. Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease. Mol. Cell. Biochem. 440, 167\u2013187 (2018).","journal-title":"Mol. Cell. Biochem."},{"key":"6431_CR37","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2337\/diab.40.3.377","volume":"40","author":"PB Duell","year":"1991","unstructured":"Duell, P. B., Oram, J. F. & Bierman, E. L. Nonenzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux. Diabetes 40, 377\u2013384 (1991).","journal-title":"Diabetes"},{"key":"6431_CR38","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.cgh.2018.04.043","volume":"17","author":"MS Siddiqui","year":"2019","unstructured":"Siddiqui, M. S. et al. Vibration-Controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 17, 156\u2013163e152 (2019).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"6431_CR39","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","volume":"66","author":"T Karlas","year":"2017","unstructured":"Karlas, T. et al. Individual patient data meta-analysis of controlled Attenuation parameter (CAP) technology for assessing steatosis. J. Hepatol. 66, 1022\u20131030 (2017).","journal-title":"J. Hepatol."},{"key":"6431_CR40","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604\u2013612 (2009).","journal-title":"Ann. Intern. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06431-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06431-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06431-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T19:20:15Z","timestamp":1751397615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06431-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6431"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-06431-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"14 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21883"}}